Cluenex
Log inStart free
All stocks · Healthcare · Health Care

Medline Inc. MDLN

Medline Inc. scores weak on business quality (4.1 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$36.26Oct 9, 2026
Business qualityWeak
Next earningsNov 4, 2026
Insiders, 90 daysQuiet

Why it matters

  1. What Medline Inc. does

    Medline distributes medical supplies and equipment to healthcare providers, generating revenue from hospitals and clinics relying on its vast product catalog. The company is leaning into large-scale distribution efficiency to capture rising demand across health systems.

  2. What it does best

    Medline operates a massive distribution network that underpins its 11.5% revenue growth. While peers like SOLV post lower growth, Medline's scale in medical supply logistics creates high volume density that smaller rivals struggle to match.

  3. The main risk

    Net debt sits at $10.6B against a total debt of $12.6B, exposing the company to high financing costs if cash flows stall or interest rates remain elevated.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityWeak

Gross margin sits at 26.2% with a thin net margin of 2.3%, showing that high revenue scale fails to translate into strong bottom-line conversion.

MoatWeak

Scale advantages lock in hospital networks through deeply integrated supply chains, though its gross margin sits in the bottom quartile at 8% sector rank.

GrowthSteady

Revenue grew 11.5% to $29.9B, accelerating from prior years as distribution volumes expand across health systems.

Financial healthFair

Total debt of $12.6B and net debt of $10.6B weigh on the balance sheet, though free cash flow reached $1.5B, leaving the financial position soft.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

No open market buys or unplanned sales by executives or directors.

Our sealed record on MDLN

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is MDLN a good business?

Medline Inc. scores weak on the Cluenex quality check (4.1 of 10), measured against its own industry. Profitability is weak, moat weak, growth steady and financial health fair.

Are insiders buying MDLN?

In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.

When does MDLN report earnings?

Nov 4, 2026.

For members

See MDLN today

  • Today's verdict on MDLN, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Medline Inc. (MDLN)”, https://cluenex.com/stocks/mdln/, data as of Oct 10, 2026.